Insider Selling: NewAmsterdam Pharma (NASDAQ:NAMS) Insider Sells 45,481 Shares of Stock

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) insider Johannes Jacob Piete Kastelein sold 45,481 shares of the company’s stock in a transaction dated Friday, February 20th. The stock was sold at an average price of $35.31, for a total value of $1,605,934.11. Following the completion of the transaction, the insider owned 53,500 shares in the company, valued at $1,889,085. This represents a 45.95% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Johannes Jacob Piete Kastelein also recently made the following trade(s):

• On Monday, January 5th, Johannes Jacob Piete Kastelein sold 6,000 shares of NewAmsterdam Pharma stock. The shares were sold at an average price of $33.25, for a total value of $199,500.00.

NewAmsterdam Pharma Stock Down 0.4%

Shares of NAMS stock traded down $0.16 during trading on Tuesday, hitting $36.01. The company had a trading volume of 755,337 shares, compared to its average volume of 702,830. The stock’s 50-day moving average is $33.98 and its two-hundred day moving average is $32.78. The stock has a market capitalization of $4.08 billion, a price-to-earnings ratio of -20.81 and a beta of 0.06. NewAmsterdam Pharma Company N.V. has a 52 week low of $14.06 and a 52 week high of $42.00.

NewAmsterdam Pharma (NASDAQ:NAMS) last announced its earnings results on Wednesday, February 18th. The company reported ($0.63) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.40) by ($0.23). The company had revenue of $0.03 million for the quarter, compared to the consensus estimate of $0.92 million. NewAmsterdam Pharma had a negative net margin of 906.22% and a negative return on equity of 26.67%. On average, research analysts predict that NewAmsterdam Pharma Company N.V. will post -1.75 EPS for the current fiscal year.

Institutional Trading of NewAmsterdam Pharma

Institutional investors have recently modified their holdings of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in NewAmsterdam Pharma in the first quarter valued at $610,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in shares of NewAmsterdam Pharma by 13.6% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 288,134 shares of the company’s stock valued at $5,898,000 after purchasing an additional 34,563 shares in the last quarter. Teacher Retirement System of Texas bought a new position in NewAmsterdam Pharma during the 2nd quarter valued at approximately $212,000. Bank of New York Mellon Corp purchased a new stake in shares of NewAmsterdam Pharma in the second quarter worth $6,392,000. Finally, Geode Capital Management LLC grew its stake in shares of NewAmsterdam Pharma by 15.9% in the second quarter. Geode Capital Management LLC now owns 99,457 shares of the company’s stock worth $1,800,000 after acquiring an additional 13,629 shares during the last quarter. 89.89% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research firms have weighed in on NAMS. HC Wainwright upgraded NewAmsterdam Pharma to a “strong-buy” rating in a research report on Thursday, February 19th. Needham & Company LLC boosted their target price on NewAmsterdam Pharma from $46.00 to $48.00 and gave the stock a “buy” rating in a research report on Wednesday, February 18th. Guggenheim upped their target price on NewAmsterdam Pharma from $41.00 to $45.00 and gave the stock a “buy” rating in a research note on Thursday, February 19th. Weiss Ratings reissued a “sell (d-)” rating on shares of NewAmsterdam Pharma in a research note on Thursday, January 22nd. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of NewAmsterdam Pharma in a report on Thursday, February 19th. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, NewAmsterdam Pharma presently has a consensus rating of “Moderate Buy” and a consensus price target of $47.00.

About NewAmsterdam Pharma

NewAmsterdam Pharma, Inc is a clinical‐stage biopharmaceutical company focused on discovering and developing novel small‐molecule therapies for cardiometabolic diseases. The company’s research efforts are aimed at addressing key unmet needs in metabolic syndrome, obesity and type 2 diabetes by modulating pathways involved in glucose regulation, energy homeostasis and lipid metabolism.

The company’s development pipeline features multiple small‐molecule candidates at various stages of preclinical and clinical evaluation.